Welcome to the e-CCO Library!

P373: Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, impact of extraintestinal manifestations and immunomediated diseases and safety
Year: 2022
Source: ECCO'22
Authors: Chaparro, M.(1);Acosta, D.(1);Rodríguez, C.(2);Vicuña, M.(2);Mesonero, F.(3);Barreiro-de Acosta, M.(4);Fernández-Clotet, A.(5);Hernández Martínez, Á.(6); Arroyo, M.T.(7);Vera Mendoza, I.(8);Sicilia, B.(9);Muñoz Villafranca, C.(10);Castro-Poceiro, J.(11);Martínez Cadilla, J.(12);Vázquez Morón, J.M.(13);Montil, E.(14);Sierra-Ausín , M.(15);Calafat, M.(16); Leo Carnerero, E.(17);Manceñido Marcos, N.(18);Torrealba M, L.(19); Alonso-Galán, H.(20); Benítez, J.M.(21);Ber Nieto, Y.(22);Cabello Tapia, M.J.(23);Diz-Lois Palomares, M.T.(24);García, M.J.(25);Armesto González, E.M.(26);Calvet Calvo, X.(27);Piqueras, M.(28);Dueñas Sadornil, C.(29); Pérez Calle, J.L.(30);Botella, B.(31); Martínez-Pérez, T.D.J.(32);Ramos, L.(33);Rodríguez-Grau, M.C.(34);Fernández Forcelledo, J.L.(35); Gutiérrez, A.(36);Sesé Abizanda, E.(37);Gisbert, J.P.(1);
Created: Friday, 11 February 2022, 3:52 PM
P373: Real-file prospective experience with adalimumab in inducing remission in ulcerative colitis in Italian primary inflammatory bowel diseases centres
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Tursi A.*1, Allegretta L.2, Della Valle N.3, Elisei W.4, Forti G.5, Faggiani R.6, Lorenzetti R.7, Mocci G.8, Penna A.9, Pranzo G.10, Paiano P.11, Ricciardelli C.11, Gallina S.6, Picchio M.12

Created: Wednesday, 20 February 2019, 10:36 AM
P374 Disease course and fate of Crohn’s perianal fistula patients following failure of initial biologic therapy: real-world lessons on the impact of refractory disease from a tertiary centre cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Adegbola, W.Y. Mak, K. Sahnan, S. Hiles, P. Bassett, P. Lung, J. Warusavitarne, O. Faiz, R. Phillips, P. Tozer, A. Hart

Created: Thursday, 30 January 2020, 10:12 AM
P374: Effects of subcutaneous vedolizumab on health-related quality of life and work productivity in patients with ulcerative colitis: results from the Phase 3 VISIBLE 1 trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Vermeire1, Ž. Krznarić2, T. Kobayashi3, J. Chen4, C. Agboton5, K. Kisfalvi4, H. Patel*6, W. Sandborn7

Created: Friday, 22 February 2019, 9:41 AM
P374: Efficacy of a micronised, dispersible ferric pyrophosphate in children with anaemia associated with inflammatory bowel disease.
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Wegner*1, G. Mierzwa2, S. Wiecek3, A. Korlatowicz- Bilar4, M. Dadalski5, B. Korczowski6, J. Kierkus7

Created: Friday, 22 February 2019, 9:49 AM
P374: Front loading infliximab dosing regimen improves outcomes in Crohn’s Disease perianal fistulas
Year: 2022
Source: ECCO'22
Authors: Lloyd, A.(1);Wilkinson, A.(2);Aleman Gonzalez, H.(2);Ramachandran, S.(2);Whitehead, E.(2);Pattinson, A.(2);Stamp, K.(2);Turnbull, J.(2);Talbot, A.(2);Sebastian, S.(2);
Created: Friday, 11 February 2022, 3:52 PM
P374: Home or hospital-based analysis of stool calprotectin: assessing two methods for monitoring inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Heida A.*1, Knol M.1, Muller Kobold A.2, Dijkstra G.3, van Rheenen P.1

Created: Wednesday, 20 February 2019, 10:36 AM
P374: Non-alcoholic fatty liver disease in inflammatory bowel disease: Prevalence and risk factors
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Losurdo1*, A. Iannone2, M. Mangia3, E. Shahini2, F. Albano2, S.F. Rizzi2, R.F. La Fortezza2, R. Lovero2, A. Contaldo2, M. Barone2, G. Leandro4, E. Ierardi2, A. Di Leo2, M. Principi2

Created: Thursday, 21 February 2019, 9:14 AM
P374: Safety and drug survival of methotrexate versus tioguanine after failure of conventional thiopurines in patients with Crohn’s disease.
Year: 2021
Source: ECCO'21 Virtual
Authors: Savelkoul, E.(1);Maas, M.(1);Bourgonje, A.(2);Crouwel, F.(3);Russel, M.(4);Römkens, T.(5);De Boer, N.(3);Dijkstra, G.(2);Hoentjen, F.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P374: Therapeutic drug monitoring can guide the intravenous-to-subcutaneous switch of infliximab and vedolizumab: a pharmacokinetic simulation study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Wang, Z.(1)*;Verstockt , B.(2,3);Sabino , J.(2,3);Ferrante , M.(2,3);Vermeire , S.(2,3);Dreesen, E.(1);
Created: Friday, 14 July 2023, 11:05 AM
P375 Feasibility of the first paediatric randomised controlled pilot trial of faecal microbiota transplant for ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. PAI2, J. Popov3, E. Hartung1, L. Hill4, K. Grzywacz5, D. Godin5, L. Thabane6, C. Lee7, M. Surette2,8,9, P. Moayyedi2,8

Created: Thursday, 30 January 2020, 10:12 AM
P375: A simulation study to evaluate the performance of a multiple imputation method to address missing data in an analysis of clinical effectiveness using the ImproveCareNow Registry of pediatric patients with Crohn’s disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Zhang, N.(1,2);Liu, C.(1);King, E.(1,2);Chen, S.(1);Olano, K.(1);Steiner, S.(3);Colletti, R.(4);Saeed, S.(5);Strauss, R.(6);Volger, S.(6);Lo, K.H.(6);Wang, Y.(6);
Created: Wednesday, 2 June 2021, 4:12 PM
P375: Faecal calprotectin variation after induction therapy with infliximab to predict clinical, endoscopic and ultrasonographic remission in Crohn’s disease patients
Year: 2022
Source: ECCO'22
Authors: Revés, J.(1);Morão, B.(1);Gomes, C.F.(1);Nascimento, C.(1);Abreu, N.(2);Gonçalves, T.C.(3);Castro, F.(3);Freitas, M.(3);Moreira, M.J.(3);Cotter, J.(3);Pereira, F.(4);Caldeira, A.(4);Sousa, R.(4);Coelho, R.(5);Macedo, G.(5);Macedo, C.(6);Ferreira, M.(6);Glória, L.(1);Torres, J.(1);Palmela, C.(1);
Created: Friday, 11 February 2022, 3:52 PM
P375: Inflammatory cutaneous lesions in inflammatory bowel disease treated with vedolizumab or ustekinumab: an ECCO CONFER multi-centre case series
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

F. M. Phillips*1, B. Verstockt2,3, S. Sebastian4,5, D. G. Ribaldone6, S. Vavricka7, K. Konstantinos8, E. Slattery9, N. de Suray10,11, C. Flores12, W. Fries13, F. Vincenzi14, E. Capoferro15, O. Bachmann16, U. Kopylov17, ECCO CONFER Investigators1

Created: Friday, 22 February 2019, 9:41 AM
P375: Intraoperative endoscopy is safe and helps to determine the resection extent in Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Podmanicky D.*1, Stefanov V.1, Harustiakova D.2, Kovacs J.3, Zelinkova Z.3

Created: Wednesday, 20 February 2019, 10:36 AM
P375: Izencitinib induction treatment in patients with moderately-to-severely-active Crohn's Disease: A phase 2 double-blind, randomized, placebo-controlled study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Schreiber, S.(1);Reinisch, W.(2);Nguyen, D.(3);Guerin, T.(4);Kierkus, J.(5);Rozpondek, P.(6);Bourdet, D.(7);Abhyankar, B.(8)*;Peyrin-Biroulet, L.(9);
Created: Friday, 14 July 2023, 11:05 AM
P375: Long-term outcomes after primary infliximab treatment failure in patients with inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Buhl*, C. Steenholdt, M. Borghede, M. Rasmussen, J. Brynskov, O. Ø. Thomsen, M.A. Ainsworth

Created: Friday, 22 February 2019, 9:49 AM
P375: Self-management in inflammatory bowel disease: A perspective of patients and caretakers
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Peek-Kuijt*, S. van den Burg, A. van der Meulen- de Jong, J. Maljaars

Created: Thursday, 21 February 2019, 9:14 AM
P376 Real life health care utilisation in paediatric patients with inflammatory bowel disease in the era of biologics
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S.A. Tchogna, X.Y. Yang, C. Deslandres, P. Jantchou

Created: Thursday, 30 January 2020, 10:12 AM
P376: Assessment of nutritional status and food related experience of adult inflammatory bowel disease inpatients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Keetarut K.*1, Bloom S.2, Qu X.3, Grimble G.3

Created: Wednesday, 20 February 2019, 10:36 AM